000538 云南白药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.13713.06712.06810.4467.822
总资产报酬率 ROA (%)6.7659.6168.9027.6445.681
投入资产回报率 ROIC (%)8.23411.62210.5248.8746.543

边际利润分析
销售毛利率 (%)30.05929.50927.89826.50626.323
营业利润率 (%)19.53114.66214.26712.3519.239
息税前利润/营业总收入 (%)19.65214.55913.81111.6568.315
净利润/营业总收入 (%)16.89512.60111.90810.5417.784

收益指标分析
经营活动净收益/利润总额(%)80.82582.35284.90383.614130.329
价值变动净收益/利润总额(%)17.07519.08716.07418.7337.353
营业外收支净额/利润总额(%)0.1980.072-0.473-0.2590.169

偿债能力分析
流动比率 (X)2.6392.6402.6562.8512.631
速动比率 (X)2.1652.1572.1662.3452.042
资产负债率 (%)25.56426.02126.54925.80527.745
带息债务/全部投入资本 (%)7.0637.6809.18611.20513.757
股东权益/带息债务 (%)1,281.1111,168.637959.228770.454607.468
股东权益/负债合计 (%)290.645283.576276.421287.336260.266
利息保障倍数 (X)236.629-127.881-35.545-17.585-8.849

营运能力分析
应收账款周转天数 (天)83.66187.77189.42887.70080.282
存货周转天数 (天)72.79177.65879.42590.395109.623